Lakewood-amedex Biotherapeutics INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Lindesfarne LLC has reported a beneficial ownership of 203,360 shares, representing 9.88% of the common stock of Lakewood-Amedex Biotherapeutics Inc., as of April 17, 2026.